Advertisement
Advertisement
KAPA
Kairos Pharma, Ltd.
0.39
USDSponsored
0.00
-1.03%
Aug 07, 15:59 UTC -4
Closed
After-Market
0.38
0.00
-1.04%
KAPA Earnings Reports
Positive Surprise Ratio
KAPA beat 0 of 7 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Kairos Pharma, Ltd. earnings per share and revenue
On May 13, 2026, KAPA reported earnings of -0.08 USD per share (EPS) for Q1 26, missing the estimate of -0.07 USD, resulting in a -4.58% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.10% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Kairos Pharma, Ltd.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Kairos Pharma, Ltd. reported EPS of -$0.08, missing estimates by -4.58%, and revenue of $0.00, 0% as expectations.
How did the market react to Kairos Pharma, Ltd.'s Q1 2026 earnings?
The stock price moved up 6.1%, changed from $0.46 before the earnings release to $0.49 the day after.
When is Kairos Pharma, Ltd. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Kairos Pharma, Ltd.'s next earnings report?
Based on --
analysts, Kairos Pharma, Ltd. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement